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Abstract
Background: Inflammation is associated with major depressive disorder (MDD). Translocator protein 18 kDa (TSPO),
a putative biomarker of neuroinflammation, is quantified using positron emission tomography (PET) and 11C-PBR28,
a TSPO tracer. We sought to (1) investigate TSPO binding in MDD subjects currently experiencing a major
depressive episode, (2) investigate the effects of antidepressants on TSPO binding, and (3) determine the relationship
of peripheral and central inflammatory markers to cerebral TSPO binding. Twenty-eight depressed MDD subjects
(unmedicated (n = 12) or medicated (n = 16)) and 20 healthy controls (HC) underwent PET imaging using 11C-PBR28.
Total distribution volume (VT, proportional to Bmax/Kd) was measured and corrected with the free fraction in plasma
(fp). The subgenual prefrontal cortex (sgPFC) and anterior cingulate cortex (ACC) were the primary regions of
interest. Peripheral blood samples and cerebrospinal fluid were analyzed to investigate the relationship between
TSPO binding and peripheral and central inflammatory markers, including interleukins and neurotrophic factors
previously linked to depression.
Results: TSPO binding was higher in MDD versus HC in the sgPFC (Cohen’s d = 0.64, p = .038, 95% CI 0.04–1.24) and
ACC (d = 0.60, p = .049, 95% CI 0.001–1.21), though these comparisons missed the corrected threshold for statistical
significance (α = .025). Exploratory analyses demonstrated that unmedicated MDD subjects had the highest level of
TSPO binding, followed by medicated MDD subjects, who did not differ from HC. TSPO binding correlated
with interleukin-5 in cerebrospinal fluid but with no other central inflammatory markers.
Conclusions: This study found a trend towards increased TSPO binding in the brains of MDD subjects, and
post hoc analysis extended these findings by demonstrating that this abnormality is significant in unmedicated (but
not medicated) MDD subjects.
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Background
Inflammation is associated with major depressive disorder
(MDD), both as a putative causal factor and as a bio-
marker of disease state and/or response to antidepressant
treatment [1, 2]. Medical illnesses associated with periph-
eral inflammation, such as rheumatoid arthritis, systemic
lupus erythematosus, and multiple sclerosis, have higher
rates of comorbid MDD compared to the general popula-
tion [3, 4]. Conversely, some pro-inflammatory markers
are normalized in individuals with MDD treated with anti-
depressant medications or electroconvulsive therapy [5–
8]. While most studies have linked MDD to increased
peripheral inflammation, central inflammation—typically
measured by evaluating inflammatory biomarkers in cere-
brospinal fluid (CSF)—has also been associated with de-
pression [9, 10], albeit less consistently.
Tumor necrosis factor-alpha (TNF-a), brain-derived
neurotrophic factor (BDNF), C-reactive protein (CRP),
and various interleukins (ILs)—including IL-5, IL-6, IL-8,
and IL-10—have been implicated in the pathophysiology
of MDD [5, 8, 11–15]. In some instances, however, the
direction of differences relative to healthy controls have
differed between peripheral and central levels of the same
cytokine, making it difficult to extrapolate peripheral ab-
normalities to the brain [10, 16].
While differences in inflammatory markers in the blood
and CSF are well-documented, it remains unclear whether
inflammatory changes manifest in the brains of MDD sub-
jects. Translocator protein 18 kDa (TSPO) is a mitochon-
drial protein that transports cholesterol to an enzyme that
synthesizes pregnenolone, which is a precursor for ste-
roids and neurosteroids [17]. Because TSPO is highly
expressed in immune and glial cells within the brain—par-
ticularly activated microglia and reactive astrocytes—it is a
potential biomarker of neuroinflammation and, further-
more, can be accurately quantified through PET [18]. A
2013 study found no differences in TSPO binding between
healthy controls and MDD subjects [19]; however, a re-
cent positron emission tomography (PET) study by Setia-
wan and colleagues found that, compared to healthy
controls, subjects with MDD had increased TSPO density
[20]. Using PET imaging and 18F-FEPPA, a radioligand for
TSPO, the authors found a positive correlation between
TSPO binding and severity of depression but observed no
correlation between TSPO binding and several peripheral
biomarkers of inflammation [20]. Thus, while neuroin-
flammation and MDD appeared to be linked in some
studies, it remains unknown whether these findings are
replicable, whether they may be influenced by antidepres-
sant treatment, and whether peripheral markers of inflam-
mation, such as TNF-alpha and other cytokines, correlate
with TSPO density.
The primary aim of this study was to investigate TSPO
binding in MDD subjects. The secondary aims were to
determine if antidepressant use affects TSPO binding and
whether TSPO binding is associated with peripheral and/or
central biomarkers of inflammation. We conducted PET
scans with medicated and unmedicated MDD subjects and
healthy controls using 11C-PBR28—a TSPO tracer and a
close chemical analog of 18F-FEPPA—as an indirect meas-
ure of neuroinflammation [21]. Both 11C-PBR28 and
18F-FEPPA are second-generation radioligands and, because
TSPO is increased not only in activated microglia but also
in reactive astrocytes, both ligands are considered able to
indirectly measure neuroinflammation. We also sampled
peripheral blood and cerebrospinal fluid to investigate the
relationship between TSPO and inflammatory markers.
Methods
Participants
Participants included 28 subjects (10 women and 18
men, aged 18 or older) diagnosed with MDD, currently
experiencing a moderate-to-severe major depressive epi-
sode (n = 12 unmedicated and n = 16 medicated, based
on current state at intake) and 20 healthy controls with
no current or prior mental health history (10 men and
10 women, aged 18 or older) (Table 1). Unmedicated
subjects were medication-free for at least 2 weeks prior
to the PET scan. All subjects were screened at the Clin-
ical Research Center of the National Institute of Mental
Health (NIMH) in Bethesda, Maryland, between January
2014 and March 2016 (ClinicalTrials.gov identifier:
NCT01851356). Participants were diagnosed with MDD
via an interview with a licensed, independent psychiatrist
and confirmed with the Structured Clinical Interview for
Axis I DSM-IV Disorders-Patient Version [22]. All sub-
jects completed the Montgomery-Asberg Depression
Rating Scale (MADRS) within 1 week prior to the PET
scan; inclusion criteria required a score ≥ 20. Exclusion
criteria were evidence of risk of imminent suicide, bipo-
lar disorder, substance abuse within 6 months, or any
comorbid illness likely to affect the subject’s inflamma-
tory status. The additional exclusion criterion for healthy
controls was any history of an Axis I diagnosis. All sub-
jects were screened for the rs6971 polymorphism on the
TSPO gene using in vitro TSPO phenotypic binding as-
says from leukocytes; six low-affinity binders (three
MDD, three controls; rate did not differ between groups)
were excluded from the study because they do not bind
appreciable amounts of TSPO ligands [23].
This study was approved by the Combined Neurosci-
ence Institutional Review Board of the National Insti-
tutes of Health. All participants gave written informed
consent before entry into the study.
11C-PBR28 PET imaging
11C-PBR28 PET scans were performed on a GE Advance
Tomograph (GE Medical Systems; Waukesha, WI). In
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two subjects, the images were instead acquired with a
high-resolution research tomograph (Siemens Medical
Solutions; Malvern, PA); images for these two subjects
were reconstructed using the same resolution and pa-
rameters used for the GE scans. After a transmission
scan for attenuation correction, 11C-PBR28 was injected
in bolus (healthy volunteers, 701 ± 19 MBq; medicated
MDD subjects, 694 ± 10 MBq; unmedicated MDD sub-
jects, 700 ± 12 MBq), and the images were acquired in
3D for 90 min. Arterial blood samples were drawn
manually at 15-s intervals for the first 2.5 min, then at 3,
4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 min. Radio-
activity in whole blood and plasma was measured by a
gamma counter, and the parent concentration was ob-
tained by high-performance liquid chromatography [24].
The free fraction of 11C-PBR28 in plasma (fP) was mea-
sured by ultrafiltration and normalized using a standard
derived from pooled donor plasma to correct for
day-to-day intra-assay variability [25] and yielded a value
of 2.85 ± 0.76%, 2.98 ± 0.76%, and 2.49 ± 0.26%, respect-
ively, for healthy volunteers, medicated, and unmedi-
cated subjects with depression. fP was not available for
one healthy control subject, so the average group value
from the other healthy controls was used.
All participants also underwent brain magnetic reson-
ance imaging (MRI) within 1 year prior to the PET scan.
T1-weighted MR images were acquired using a 3T Phi-
lips Achieva scanner (Bothell, WA) with turbo field echo
sequence (repetition time = 8.1 ms, echo time = 3.7 ms,
flip angle = 8, matrix = 181 × 256 × 256, voxel size = 1 ×
0.983 × 0.983 mm).
PET brain time-activity curves were obtained with the
Pneuro module of Pmod 3.8 (Zurich, Switzerland).
Image pre-processing—such as coregistration between
PET and MR, segmentation, and atlas normalization—
was performed with the Pneuro pipeline. The regions of
interest were automatically defined using the Hammers’
probabilistic brain atlas [26].
Selection of brain regions
In order to reduce the likelihood of type II errors, we se-
lected two regions of interest a priori: the anterior cingu-
late cortex (ACC) and the subgenual prefrontal cortex
(sgPFC). These regions were selected because they have
been shown to differ in individuals with MDD using mul-
tiple imaging modalities [27–30] and often normalize fol-
lowing antidepressant treatment [8]. Increased microglial
quinolinic acid immunoreactivity in specific subregions of
the ACC further underscores the involvement of these re-
gions and supports the role of the immune system in the
pathophysiology of MDD [31]. Seventy-five brain regions
from both hemispheres—including the insula, putamen,
thalamus, hippocampus, and cerebellum—were included
in a secondary analysis to determine if changes in TSPO
binding were more region-specific or globally distributed
in the brain.
ACC and sgPFC values were obtained by averaging the
left and right sides of each region. The sgPFC region
was obtained by merging the subgenual, subcallosal, and
presubgenual areas of the Hammers’ atlas.
11C-PBR28 PET imaging data analysis
At the regional level, total distribution volume (VT)
was calculated using a two-tissue compartmental model
and a metabolite-corrected arterial input function fitted
to a tri-exponential function. Brain data were weighted
frame-wise by assuming that the inverse square root
of noise-equivalent counts was proportional to the
Table 1 Demographic information
Healthy controls MDD-unmedicated MDD-medicated
(n = 20) (n = 12) (n = 16)
Mean SD Mean SD Mean SD F (2,45) p
Age 31.60 10.36 33.80 8.66 44.60 9.74 8.54 .001
BMI (kg/m2) 26.01 4.06 27.50 5.29 28.10 4.99 0.93 .40
Age of onset (years) – – 18.42 5.6 17.81 5.59 0.08 .78
Current episode (months) – – 40.67 59.55 57.44 92.86 0.30 .59
Length of illness (years)a – – 16.21 8.75 26.98 10.42 8.19 .008
MADRS total score 0.30 0.57 31.75 3.62 31.00 4.40 573.73 < .0001
n % n % n % X2 p
Sex (female) 10 50 5 42 6 38 0.59 .74
Race (Caucasian) 10 50 9 75 15 94 8.37 .02
Binding affinity (high) 12 60 10 83 9 56 2.51 .29
MDD major depressive disorder, BMI body mass index, MADRS Montgomery-Asberg Depression Rating Scale
aMissing data for n = 1 in MDD-medicated
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normalized standard deviation of each frame. The arterial
whole blood curve was used to correct for activity in the
vascular component, assuming that the blood volume is
5% of the total brain volume. The delay between the ar-
rival of the radioligand to the brain and to the radial artery
was estimated by fitting the whole brain curve. VT values
were then corrected for fP to obtain the final outcome par-
ameter VT/fP. Uncorrected VT values were also compared
to test the robustness of these findings. Genotype (mixe-
d-affinity vs high-affinity) was added as a covariate to all
models.
At the voxel level, we calculated first the parametric
images with the Logan plot and divided each image by
the individual free fraction. The VT/fP images of the
three groups were then normalized and smoothed with
an 8-mm Gaussian filter. Using SPM12 (Wellcome
Trust, London, UK), an ANCOVA model was used for
the comparison between the groups with the diagnosis
and the genotype status as fixed factors and age and
BMI as covariates. We first created significance map
with cutoff p < 0.005 uncorrected for multiple compari-
sons and then applied cluster-wise correction for mul-
tiple comparisons with cluster-level cutoff p < 0.05.
Peripheral and central biomarker analysis
All subjects provided peripheral blood samples, which
were collected using the vacutainer system within 2 h
before the PET scan. Blood samples were centrifuged at
3000 rpm at 4 °C for 10 min and stored at − 80 °C. For
those who consented (n = 6 healthy controls, n = 4 un-
medicated MDD, n = 10 medicated MDD), up to 15 mL
CSF was collected within 1 week following the PET scan
and immediately placed in liquid nitrogen and stored at
− 80 °C.
The following peripheral and central markers of in-
flammation were examined as correlates of TSPO bind-
ing (see Additional file 1 for specific methods): vascular
endothelial growth factor (VEGF), IL-6, IL-8, amyloid
A1, adiponectin, BDNF (plasma only, not detected in
CSF), TNF-alpha (plasma only), CRP (plasma only), IL-2
(CSF only, not detected in plasma), IL-5 (CSF only), and
interferon-gamma (CSF only).
Statistical analysis
The general linear model was used to evaluate the primary
hypothesis, which was that TSPO binding is elevated
among patients with MDD relative to HC, and the second-
ary hypothesis, which was that antidepressant use among
MDD patients, would be associated with normalized TSPO
binding. Genotype was entered as a covariate; no other co-
variates were specified a priori (see Additional file 1 for
additional information). Partial Pearson correlations were
used to evaluate the relationship between TSPO binding
and inflammatory markers; body mass index (BMI) was
added as a covariate in these analyses. Alpha was set to
.025 per region (ACC and sgPFC) for the primary aim, and
alpha for the secondary and exploratory aims was un-
adjusted (.05). Cohen’s d effect sizes (with 95% CI) were
calculated using least square mean difference estimates
and associated degrees of freedom. Data were analyzed
using SAS/STAT Version 9.4.
Results
Demographic information is presented in Table 1. Most
(n = 15) subjects in the medicated MDD group were on
multiple psychoactive medications (median = 2.5) includ-
ing selective serotonin reuptake inhibitors, serotonin-
norepinephrine reuptake inhibitors, serotonin modula-
tors, tricyclic antidepressants, and/or other psychiatric
medications (see Additional file 1 for additional informa-
tion on concomitant medications).
There was a trend towards higher TSPO binding in
MDD versus HC (sgPFC: Cohen’s d = 0.64, p = .038, 95%
CI 0.04–1.24; ACC: d = 0.60, p = .049, 95% CI 0.001–1.21),
though these comparisons missed the corrected signifi-
cance threshold (α = .025) (see Fig. 1, Additional file 1:
Table S1). In secondary analyses, TSPO binding was high-
est in unmedicated MDD participants, followed by medi-
cated MDD participants and HC, which did not differ
from one another (see Fig. 2, Additional file 1: Table S2).
For both sgPFC and ACC, the differences between un-
medicated MDD participants and HC were large (in both
regions p = .005, d = 0.89, 95% CI 0.28–1.50) while the dif-
ferences between unmedicated and medicated MDD par-
ticipants were moderate (sgPFC: p = .056, d = 0.59, 95% CI
− 0.02–1.20; ACC: p = .04, d = 0.64, 95% CI 0.03–1.25).
This pattern of results was consistent across most re-
gions of interest (see Additional file 1: Tables S3 and S4).
Sensitivity analyses using uncorrected VT yielded consist-
ent results for MDD versus HC, but all between-group
comparisons among unmedicated MDD, medicated
MDD, and HC were non-significant (see Additional file 1:
Table S5).
Similar to region analysis, the voxel-wise comparison
showed higher 11C-PBR28 binding across several regions
of the brain of unmedicated MDD subjects compared to
healthy controls. Areas of significant difference, after
correction for multiple comparisons, were spread mostly
across the frontal and temporal lobes, bilaterally (Fig. 3).
Even for the liberal uncorrected threshold of p < 0.005,
no cluster survived the correction for multiple compari-
sons when calculating the difference between medicated
subjects and healthy controls and the difference between
medicated and unmedicated subjects.
We explored whether any particular drug class was as-
sociated with decreased binding. Among the total MDD
group, the number of drug classes prescribed was not re-
lated to TSPO binding (p = .40). No individual drug class
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was associated with TSPO binding (all p > .10). However,
because the number of participants prescribed any given
drug class was small (see Additional file 1), the power to
detect an effect of a given class was low.
No covariates in addition to genotype were specified a
priori. However, differences between groups in age and
race were observed (see Table 1). Further, a recent study
from our laboratory suggested that age is associated with
increased TSPO binding in healthy subjects [32], and at
least one prior study documented a negative and moder-
ately sized correlation between BMI and TSPO VT in se-
lect brain regions [20]. For these reasons, analyses
including age, race, and BMI as additional covariates
were performed.
The addition of covariates did not alter the interpret-
ation of the MDD versus HC analyses (see Additional file 1:
Table S1). However, the introduction of additional covari-
ates strengthened the differences between the medicated
and unmedicated MDD patients, and between the un-
medicated MDD patients and HC, while the medi-
cated MDD patients remained undifferentiated from
HC (see Additional file 1: Table S2).
Length of illness in MDD subjects was not related
to TSPO binding (sgPFC: r = .15, p = .46; ACC: r = .13,
Fig. 2 Translocator protein (TSPO) binding in the subgenual prefrontal cortex (sgPFC) (a) and anterior cingulate cortex (ACC) (b) among healthy
controls and medicated and unmedicated patients with a major depressive disorder (MDD). Groups are compared using ANCOVA, controlling
for genotype
Fig. 1 Translocator protein (TSPO) binding in the subgenual prefrontal cortex (sgPFC) (a) and anterior cingulate cortex (ACC) (b) in individuals
with a major depressive disorder (MDD) (n = 28) and healthy controls (n = 20). Groups are compared using ANCOVA, controlling for genotype
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p = .52), and in MDD, TSPO binding did not correlate
with MADRS score (sgPFC: r = − .09, p = .65; ACC: r =
− .11, p = .56). After controlling for BMI, there were no
significant between-group (MDD vs HC) differences in in-
flammatory marker concentrations (data not shown). Only
plasma adiponectin and CSF IL-5 were found to be corre-
lated with TSPO binding (Table 2).
Discussion
We found increased TSPO binding in the ACC and
sgPFC (which were the two regions specified a priori)
and throughout the brain of subjects with MDD repli-
cating recent findings [20]. Because increased TSPO
binding is an indirect marker of neuroinflammation,
these results collectively provide evidence that neuroin-
flammation is increased in unmedicated MDD subjects
and support brain inflammation as a therapeutic target
for novel medication interventions. These findings con-
trast with a prior study that found no difference in
TSPO binding between MDD subjects and healthy con-
trols [19]; however, our study differs from that one in
that we had a larger sample (n = 48 vs 22), with depres-
sion that was more severe (average MADRS = 31.5 vs
19.7) and current (in the previous study, some MDD
participants had no current symptoms). We also ob-
served no correlation with MADRS ratings, suggesting
that TSPO is not a marker of disease severity in this
subject population.
Consistent with the work of Setiawan and colleagues
[20], two additional studies demonstrated increased
TSPO binding in the brain of patients with MDD [33,
34]. This finding is true when different TSPO radioli-
gands are used (11C-PBR28 vs 18F-FEPPA). A fourth,
smaller (n = 10) study documented decreased TSPO
binding in MDD, but that study excluded patients with
elevated plasma concentrations of C-reactive protein,
which may be the subset most likely to show increased
Fig. 3 Statistical significance maps rendered on axial slices and semi-inflated surface showing increase in 11C-PBR28 binding in unmedicated
depressed patients compared to healthy controls (a). b The same analysis is restricted to high-affinity binder subjects, done with the more
stringent threshold of p < 0.001. Only clusters with threshold p < 0.05 for cluster-wise multiple comparisons are displayed. The color bar represents
T values. The same comparison using only mixed-affinity binders yielded no significant differences, but the unmedicated group comprised only
two mixed-affinity binders
Table 2 Partial Pearson correlations, controlling for body mass
index, between TSPO binding and central and peripheral markers
of inflammation
Plasma (n = 48) Cerebrospinal fluid
(n = 20)
sgPFC ACC sgPFC ACC
Interleukin 2 – – 0.01 −0.04
Interleukin 5 – – − 0.59* − 0.53*
Interleukin 6 − 0.16 − 0.15 − 0.25 −0.26
Interleukin 8 0.09 0.12 −0.19 −0.23
Brain-derived neurotrophic factor 0.25 0.23 – –
Vascular endothelial growth factor 0.16 0.20 −0.43 −0.39
Interferon-gamma – – − 0.39 −0.30
Tumor necrosis factor alpha −0.01 0.02 – –
C-reactive protein −0.07 −0.08 – –
Amyloid A1 − 0.23 −0.23 − 0.40 −0.43
Adiponectin 0.29* 0.29* 0.01 0.01
sgPFC subgenual prefrontal cortex, ACC anterior cingulate cortex, – data
not available
*p ≤ .05
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TSPO in the brain [19]. Thus, this study is the fourth of
five to find increased TSPO binding in MDD.
We found that TSPO binding in unmedicated MDD,
but not medicated MDD, differed from healthy controls.
This suggests that antidepressant treatment itself might
normalize TSPO density, even without resolving depres-
sive symptoms. Antidepressant medications have been
shown to decrease levels of several peripheral inflamma-
tory markers, including CRP and IL-6 [35, 36]. It is also
possible that some SSRIs may decrease microglial activa-
tion by inhibiting elevations in intracellular calcium [37].
An experimental study is required to definitively address
this question.
We note that although the TSPO density of the medi-
cated MDD did not differ from healthy controls, these
subjects were still depressed. This suggests that any
anti-inflammatory effects of antidepressant medication,
which are thought to act via indirect effects on the inflam-
matory system, are not sufficient for antidepressant re-
sponse, though they may still be an important target in a
subset of patients. The heterogeneity of MDD highlights
the importance of identifying subgroups that may respond
to specific interventions. Similar to other studies where
subject enrichment helped elucidate specific subgroups
who may respond to particular antidepressant interven-
tions (e.g., elevated CRP in studies of inflammation and
depression) [38], administering anti-inflammatory treat-
ment interventions to MDD subjects selected for in-
creased TSPO binding may be key to future studies.
Finally, we found that TSPO binding in the sgPFC and
ACC correlated significantly and moderately with CSF
IL-5 levels; however, no correlation with other peripheral
or central markers of inflammation was observed. Over-
all, no difference in baseline levels of peripheral inflam-
mation was observed between groups, indicating that
TSPO binding is not simply a manifestation of changes
in underlying baseline peripheral inflammation. These
findings suggest that we have yet to identify a specific
peripheral blood-based biomarker that may help us
understand or predict the inflammatory changes that
occur in the brains of subjects experiencing a major de-
pressive episode. Nevertheless, the findings also suggest
that additional investigation into IL-5—a key mediator
of eosinophil activation—is needed. Some studies have
implicated IL-5 in major depressive episodes [5, 39],
though others found no significant difference in IL-5
levels between MDD subjects and healthy controls [3].
Our inability to identify biomarkers in CSF or plasma
that correlate with TSPO binding likely indicates two
key issues, namely, the heterogeneity of the underlying
factors contributing to MDD and the limitations of cur-
rently available methods for detecting very small changes
in blood/CSF biomarker concentrations. Notably, other
cytokines and neurotrophic factors have been associated
with psychiatric illness and may warrant further investi-
gation. Examples include IL-1 and TGF, which have been
implicated in the pathophysiology of multiple psychiatric
disorders [40, 41].
Despite these interesting findings, the study has sev-
eral limitations. First, although increased TSPO has
been found in several CNS disorders with localized or
widespread neuroinflammation, its cellular localization
is not specific activated microglia, which are arguably
viewed as the major source of cytokines in the brain.
For example, TSPO is also found in astrocytes, includ-
ing especially high densities in astroglyosis or scars that
appear to have no currently active inflammatory pro-
cesses [42]. In addition, immunohistochemical studies
have found that TSPO is associated with vascular endo-
thelium [43]. Although immunohistochemistry lacks
the resolution to separate vascular endothelium from
the immediately adjacent foot processes of astrocytes,
this component of total TSPO binding is certainly not
microglial in origin.
Conclusions
In summary, the relative distribution of TSPO among cells
of the brain is unknown, and the increased uptake mea-
sured in large regions of the brain with PET and their dif-
fering roles, related or unrelated to neuroinflammation,
are yet to be clarified. Second, measuring VT/fp requires
frequent arterial sampling from the subject. While PET
studies using TSPO ligands in other disease states (e.g.,
Alzheimer’s disease) have reference regions that may be
used instead of arterial sampling [44], the universal in-
creases in TSPO binding observed in unmedicated MDD
subjects indicate that no reference region exists in the
brain and that arterial sampling will be required to meas-
ure differences between patients and controls.
Finally, it should be noted that in the field of mental
health, replication studies are rare—largely due to the het-
erogeneity of patients, relatively small sample sizes avail-
able for research studies, and slight differences in
experimental design—and the same is true in PET im-
aging studies. Such research ensures that future planned
studies are as informed as possible and allow us, as a field,
to move forward in our search to understand the patho-
physiology of MDD and develop potential treatments for
this devastating disorder. Regarding the present findings,
future work may pool the data from this study with others
to increase power and generalizability.
In conclusion, TSPO binding is increased in the brains
of MDD subjects, and this appears to be diminished with
antidepressant treatment. This indirect measurement of
neuroinflammation during major depressive episodes sug-
gests that inflammation should continue to be a focus in
developing novel therapeutics for the treatment of MDD.
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Additional file
Additional file 1: Table S1. Results of ANCOVAs comparing TSPO
binding (VT/fP) in MDD patients to healthy controls (HC). Table S2. Results
of ANCOVAs comparing TSPO binding (VT/fP) in MDD patients with and
without antidepressant medication to healthy controls (HC). Table S3
Results of ANCOVAs comparing TSPO binding (VT/fP) in MDD patients to
healthy controls (HC) in additional representative regions of interest from
the right hemisphere. Table S4. Results of ANCOVAs comparing TSPO
binding (VT/fP) in healthy controls (HC) to medicated and unmedicated
patients with MDD in additional representative regions of interest from
the right hemisphere. Table S5. Results of sensitivity analyses using VT.
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